Molecular Partners AG Net Income
| MOLN Stock | USD 4.61 0.00 0.00% |
As of the 16th of February 2026, Molecular Partners secures the Mean Deviation of 2.36, risk adjusted performance of 0.0525, and Downside Deviation of 2.92. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Partners, as well as the relationship between them.
Molecular Partners Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 3.8144 | Earnings Share (2.10) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -48.6 M | -46.2 M | |
| Net Loss | -62.1 M | -59 M | |
| Net Income Applicable To Common Shares | 135.5 M | 142.3 M | |
| Net Loss | (1.83) | (1.73) | |
| Net Income Per E B T | 1.15 | 1.10 |
Molecular | Net Income | Build AI portfolio with Molecular Stock |
Evaluating Molecular Partners's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Molecular Partners AG's fundamental strength.
Latest Molecular Partners' Net Income Growth Pattern
Below is the plot of the Net Income of Molecular Partners AG over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Molecular Partners financial statement analysis. It represents the amount of money remaining after all of Molecular Partners AG operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Molecular Partners' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Partners' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (54.04 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Molecular Net Income Regression Statistics
| Arithmetic Mean | (18,282,353) | |
| Geometric Mean | 17,904,344 | |
| Coefficient Of Variation | (242.19) | |
| Mean Deviation | 31,995,757 | |
| Median | (25,430,000) | |
| Standard Deviation | 44,278,440 | |
| Sample Variance | 1960.6T | |
| Range | 181.6M | |
| R-Value | (0.37) | |
| Mean Square Error | 1798.1T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | (3,283,112) | |
| Total Sum of Squares | 31369.3T |
Molecular Net Income History
Other Fundumenentals of Molecular Partners
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Molecular Partners Net Income component correlations
Molecular Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Molecular Partners is extremely important. It helps to project a fair market value of Molecular Stock properly, considering its historical fundamentals such as Net Income. Since Molecular Partners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Molecular Partners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Molecular Partners' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Molecular diversify its offerings? Factors like these will boost the valuation of Molecular Partners. Expected growth trajectory for Molecular significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Molecular Partners data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Molecular Partners' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Molecular Partners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Partners' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Partners.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Molecular Partners on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment in Molecular Partners over 90 days. Molecular Partners is related to or competes with Elicio Therapeutics, Corbus Pharmaceuticals, Milestone Pharmaceuticals, Cardiff Oncology, Rani Therapeutics, Nkarta, and PepGen. Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and... More
Molecular Partners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Partners' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Partners AG upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.92 | |||
| Information Ratio | 0.0325 | |||
| Maximum Drawdown | 14.54 | |||
| Value At Risk | (5.18) | |||
| Potential Upside | 4.73 |
Molecular Partners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Partners' standard deviation. In reality, there are many statistical measures that can use Molecular Partners historical prices to predict the future Molecular Partners' volatility.| Risk Adjusted Performance | 0.0525 | |||
| Jensen Alpha | 0.1261 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.0332 | |||
| Treynor Ratio | 0.3053 |
Molecular Partners February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0525 | |||
| Market Risk Adjusted Performance | 0.3153 | |||
| Mean Deviation | 2.36 | |||
| Semi Deviation | 2.67 | |||
| Downside Deviation | 2.92 | |||
| Coefficient Of Variation | 1785.69 | |||
| Standard Deviation | 2.98 | |||
| Variance | 8.88 | |||
| Information Ratio | 0.0325 | |||
| Jensen Alpha | 0.1261 | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | 0.0332 | |||
| Treynor Ratio | 0.3053 | |||
| Maximum Drawdown | 14.54 | |||
| Value At Risk | (5.18) | |||
| Potential Upside | 4.73 | |||
| Downside Variance | 8.55 | |||
| Semi Variance | 7.16 | |||
| Expected Short fall | (2.76) | |||
| Skewness | 0.0934 | |||
| Kurtosis | 0.1026 |
Molecular Partners Backtested Returns
Molecular Partners appears to be slightly risky, given 3 months investment horizon. Molecular Partners has Sharpe Ratio of 0.076, which conveys that the firm had a 0.076 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Molecular Partners, which you can use to evaluate the volatility of the firm. Please exercise Molecular Partners' Mean Deviation of 2.36, risk adjusted performance of 0.0525, and Downside Deviation of 2.92 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Molecular Partners holds a performance score of 6. The company secures a Beta (Market Risk) of 0.51, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Molecular Partners' returns are expected to increase less than the market. However, during the bear market, the loss of holding Molecular Partners is expected to be smaller as well. Please check Molecular Partners' treynor ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Molecular Partners' current price movements will revert.
Auto-correlation | 0.17 |
Very weak predictability
Molecular Partners AG has very weak predictability. Overlapping area represents the amount of predictability between Molecular Partners time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Partners price movement. The serial correlation of 0.17 indicates that over 17.0% of current Molecular Partners price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | 0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Molecular Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Molecular Partners AG reported net income of (54.04 Million). This is 115.84% lower than that of the Biotechnology sector and 177.15% lower than that of the Health Care industry. The net income for all United States stocks is 109.46% higher than that of the company.
Molecular Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in net income category among its peers.
Molecular Partners ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Molecular Partners' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Molecular Partners' managers, analysts, and investors.Environmental | Governance | Social |
Molecular Partners Institutional Holders
Institutional Holdings refers to the ownership stake in Molecular Partners that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Molecular Partners' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Molecular Partners' value.| Shares | Suvretta Capital Management, Llc | 2025-06-30 | 2.2 M | Bvf Inc | 2025-06-30 | 1.4 M | Ubs Group Ag | 2025-06-30 | 10.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 367 | Bank Of America Corp | 2025-06-30 | 157 | Rhumbline Advisers | 2025-06-30 | 0.0 |
Molecular Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 31.89 M | ||||
| Shares Outstanding | 37.4 M | ||||
| Shares Owned By Institutions | 9.60 % | ||||
| Number Of Shares Shorted | 16.41 K | ||||
| Price To Earning | 1.85 X | ||||
| Price To Book | 1.39 X | ||||
| Price To Sales | 199.56 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | (40.4 M) | ||||
| EBITDA | (51.65 M) | ||||
| Net Income | (54.04 M) | ||||
| Cash And Equivalents | 267.13 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 2.44 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.37 X | ||||
| Book Value Per Share | 3.32 X | ||||
| Cash Flow From Operations | (59.25 M) | ||||
| Short Ratio | 2.81 X | ||||
| Earnings Per Share | (2.10) X | ||||
| Target Price | 12.11 | ||||
| Number Of Employees | 158 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 172.22 M | ||||
| Total Asset | 158.53 M | ||||
| Retained Earnings | (246.29 M) | ||||
| Working Capital | 143.5 M | ||||
| Net Asset | 158.53 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
| 0.55 | DRMA | Dermata Therapeutics | PairCorr |
| 0.54 | VCEL | Vericel Corp Ord | PairCorr |
| 0.52 | PHARM | Pharming Group NV | PairCorr |
| 0.51 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.48 | OSE | OSE Pharma SA | PairCorr |
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could Molecular diversify its offerings? Factors like these will boost the valuation of Molecular Partners. Expected growth trajectory for Molecular significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Molecular Partners data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Molecular Partners' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.